Literature DB >> 25694252

[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Con].

R A Linker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25694252     DOI： 10.1007/s00115-014-4246-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  5 in total

Review 1.  Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.

Authors:  Mark S Freedman; Bruce Hughes; Daniel D Mikol; Randy Bennett; Brian Cuffel; Vamil Divan; Nicole LaVallee; Ahmad Al-Sabbagh
Journal:  Eur Neurol       Date:  2008-04-25       Impact factor: 1.710

2.  The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.

Authors:  Magnhild Sandberg-Wollheim; Gabrielle Kornmann; Dorina Bischof; Margaretha Stam Moraga; Brian Hennessy; Enrica Alteri
Journal:  Mult Scler       Date:  2011-04       Impact factor: 6.312

3.  Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.

Authors:  Magnhild Sandberg-Wollheim; Enrica Alteri; Margaretha Stam Moraga; Gabrielle Kornmann
Journal:  Mult Scler       Date:  2011-01-10       Impact factor: 6.312

4.  Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis.

Authors:  Kathrin S Utz; Jana Hoog; Andreas Wentrup; Sebastian Berg; Alexandra Lämmer; Britta Jainsch; Anne Waschbisch; De-Hyung Lee; Ralf A Linker; Thomas Schenk
Journal:  Ther Adv Neurol Disord       Date:  2014-11       Impact factor: 6.570

5.  New natural history of interferon-beta-treated relapsing multiple sclerosis.

Authors:  Maria Trojano; Fabio Pellegrini; Aurora Fuiani; Damiano Paolicelli; Valentina Zipoli; Giovanni B Zimatore; Elisabetta Di Monte; Emilio Portaccio; Vito Lepore; Paolo Livrea; Maria Pia Amato
Journal:  Ann Neurol       Date:  2007-04       Impact factor: 10.422
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.